These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 1247126

  • 1. Antiparkinsonian agents and fluphenazine decanoate.
    Idzorek S.
    Am J Psychiatry; 1976 Jan; 133(1):80-2. PubMed ID: 1247126
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G, Annable L, Ross-Chouinard A.
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms.
    Omi T, Mitsui Y, Matsunaga H.
    J Clin Pharm Ther; 2018 Feb; 43(1):117-120. PubMed ID: 28718220
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL, Kelly MW.
    Am J Hosp Pharm; 1994 Apr 01; 51(7):895-9. PubMed ID: 7912473
    [Abstract] [Full Text] [Related]

  • 10. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
    MacCrimmon DJ, Saxena B, Foley P, Grof P.
    Neuropsychobiology; 1978 Apr 01; 4(6):360-5. PubMed ID: 692838
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
    McLaren S, Cookson JC, Silverstone T.
    Int Clin Psychopharmacol; 1992 Nov 01; 7(2):67-72. PubMed ID: 1487623
    [Abstract] [Full Text] [Related]

  • 14. A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial.
    Dencker SJ, Frankenberg K, Malm U, Zell B.
    Acta Psychiatr Scand Suppl; 1973 Nov 01; 241():101-18. PubMed ID: 4147508
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fluphenazine enanthate induced decompensations.
    Van Putten T, Mutalipassi LR.
    Psychosomatics; 1975 Nov 01; 16(1):37-40. PubMed ID: 1178807
    [No Abstract] [Full Text] [Related]

  • 18. Extrapyramidal symptoms in the course of fluphenazine treatment.
    Bastecký J, Vinar O, Taussigová D.
    Act Nerv Super (Praha); 1972 Nov 01; 14(2):97-9. PubMed ID: 5040184
    [No Abstract] [Full Text] [Related]

  • 19. [Double-blind study of domestic penfluridol and fluphenazine decanoate].
    Shu L.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1983 Jun 01; 16(3):141-5. PubMed ID: 6653230
    [No Abstract] [Full Text] [Related]

  • 20. The use of fluphenazine enanthate in psychotic patients.
    Routsonis KG, Photiadis H.
    Curr Ther Res Clin Exp; 1973 Mar 01; 15(3):92-6. PubMed ID: 4196232
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.